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RNA interference (RNAi) technology provides a powerful molecular tool to reduce an expression of selected genes in eukaryotic
cells. Short interfering RNAs (siRNAs) are the effector molecules that trigger RNAi. Here, we describe siRNAs that discriminate
between the wild type and mutant (1174 C→G) alleles of human Presenilin1 gene (PSEN1). This mutation, resulting in L392V
PSEN1 variant, contributes to early onset familial Alzheimer’s disease. Using the dual fluorescence assay, flow cytometry and
fluorescent microscopy we identified positions 8th–11th, within the central part of the antisense strand, as the most sensitive
to mismatches. 2-Thiouridine chemical modification introduced at the 3′-end of the antisense strand improved the allele
discrimination, but wobble base pairing adjacent to the mutation site abolished the siRNA activity. Our data indicate that siRNAs
can be designed to discriminate between the wild type and mutant alleles of genes that differ by just a single nucleotide.
1. Introduction
Alzheimer’s disease (AD) is the most common form of
a progressive dementia in humans. The most frequently
occurring variant is a “late-onset” (LOAD), sporadic form
of the disease developing usually after age 65. The LOAD
appears as a result of a complex interaction among envi-
ronmental factors and individual predisposing genetic traits.
Almost sixty years ago, Sjo¨gren et al. demonstrated that some
patients with AD had an autosomal dominant Mendelian
pattern of disease inheritance [1]. Early onset familial cases
of Alzheimer’s disease (FAD) are rather rare and account
for only a few percent of the total population of patients
but in this form disease symptoms appear at an unusually
early age, between 30–50 year of life. Mutations in the three
genes coding Amyloid Precursor Protein (APP), Presenilin
1 (PSEN1), and Presenilin 2 (PSEN2) were identified as
responsible for development of the dementia in almost 50%
of patients with FAD. Identification of the amyloid-beta
(Aβ) peptides isolated from brains of patients with AD
and trisomy 21 (Down syndrome) suggested localization of
the parent APP gene on chromosome 21 [2–5]. Linkage
to disease mapped in FAD families led to the discovery of
the first autosomal dominant missense mutations in APP
segregating with disease risk [6]. This was followed by
identifications of autosomal dominant FAD mutations in
the PSEN1 [7] and PSEN2 [8, 9] genes, on chromosomes
14 and 1, respectively. The summary of FAD mutations is
maintained at the Alzheimer’s Disease and Frontotemporal
Dementia Mutation Database [10]. Accordingly, there are
currently described totally 227 sequence defects in the
human FAD genes: 32 mutations in APP gene, 181 mutations
in PSEN1 gene, and 14 mutations in PSEN2 gene, identified,
respectively, in 89, 399, and 23 families.
Human Presenilin 1 (PSEN1, called alternatively as
PS1, AD3, FAD, S182) is a 467-residues, ∼50 kDa protein
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with 9-TMD (transmembrane domain) topology [11, 12].
PSEN1 together with nicastrin (Nct), anterior pharynx-
defective-1 (APH-1) and presenilin enhancer-2 (PEN-2)
constitutes a multisubunit membrane-bound protease com-
plex of γ-secretase and is essential for its activity, stability
and interaction between all γ-secretase components [13–
15]. In the γ-secretase complex, Presenilin 1 is cleaved,
in intramolecular autocatalytic event, into N- and C-
terminal fragments (∼30 kDa NTF and 20 kDa CTF), which
form an active heterodimer. Several mutations in PSEN1
gene, detected in FAD patients, can inhibit processing of
polypeptide chain. The most well-studied PSEN1 function
in γ-secretase complex is catalysis of the intramembranous
cleavage of a number of proteins, for example, Notch, APP,
N-, and E-cadherins. Due to the fact that only a fraction
of cellular protein actually forms the γ-secretase complex
[16], it was postulated that Presenilin 1 may have functions
beyond those of the γ-secretase complex. For example it is
involved in neuronal Ca2+ signaling and homeostasis [17],
and it also interacts with and stabilizes β-catenin [18, 19].
The main role of the γ-secretase is participation in the APP
processing. The CTF 83 and CTF 99 fragments of APP,
formed after its proteolysis by α- or β-secretases, respectively,
are cleaved within their transmembrane regions to release
the C-terminal domain (AICD) and generate Aβ peptides.
Nearly 90% of the secreted amyloid peptides are Aβ40 or
shorter forms, while the remaining 10% are Aβ42 or longer
peptides. AD-linked mutations in PSENs genes influence the
γ-secretase cleavage-site specificity, favouring cleavage at the
position 42 relative to the position 40, thus increasing the
Aβ42/Aβ40 ratio. Research from the 1990s indicates that
mutations in the PSEN1 gene may be responsible for 30–
60% of early onset Alzheimer’s cases. The hydrophilic loop
(amino acids 263–407) of PSEN1, in which many pathogenic
mutations are localized, appears to be crucial for the protein
function, since it includes the binding domains to different
PSEN1 partners [20].
Dominantly inherited disorders constitute particularly
attractive targets for allele-specific gene silencing by short
interfering RNAs due to the fact that patients with these
disorders carry both the wild type gene and mutant allele
causing the disease. Specific silencing of a mutant allele
that expresses the toxic form of the protein, without
reducing the level of the wild type allele, might constitute
a promising approach for the cure or prevention of such
disorders. Most of the disease-associated genes differ by
a single point mutation, making them targets of choice
for allele-specific silencing. The list of trials on silencing
mutant alleles associated with neurodegenerative disorders
includes Huntington disease (HD) [21–27], Parkinson dis-
ease (PD) [28], amyotrophic lateral sclerosis (ALS) [29–
33], spinocerebellar ataxia (SCA) Type 1 (SCA1) [34],
and Type 3 (SCA3) causing Machado-Joseph disease [35,
36], frontotemporal dementia with Parkinsonism linked to
chromosome 17 (FTDP-17) [35], slow channel congenital
myasthenic syndrome (SCCMS) [37], and prion protein-
induced disease [38]. Although several studies have used
RNAi to investigate the effect of silencing of PSEN1 and
its homolog PSEN2 on γ-secretase processing and cell
metabolism [39, 40], to our best knowledge no studies have
been reported on the allele-specific silencing of any PSEN1
mutant allele. Mutation L392V in PSEN1 carries the single
nucleotide substitution (C→G) at position 1174 of coding
sequence in exon 11, followed by amino acid substitution
(Leu→Val) at the position 392 of polipeptide chain in TMD
7. Mutant form of PSEN1 is involved in the production of
longer forms of the Aβ peptide resulting in its accumulation
in the brain, and, in consequence, generation of early-
onset Alzheimer’s disease. Mean age onset of the disease in
patients with L392V PSEN1 mutation was determined as
42.5 years and mean age of death was determined as 52.6
years [10]. According to data from Alzheimer’s Disease and
Frontotemporal DementiaMutation Database, this mutation
has been already found in 50 patients with FAD in European
(Italy, France) and Asian (Japan) population [10, 41–46].
We selected the L392V mutant and wild type alleles of
Presenilin 1 as a model system for the evaluation of allele-
specificity of siRNA duplexes. A series of siRNA molecules
fully complementary to the mutant gene were screened first
by a dual fluorescence assay, then by FACS flow cytometry
and their activity was confirmed by fluorescence microscopy
and observation of reduced level of Aβ42 determined by
ELISA. Our data suggest that siRNAs can be designed to
discriminate between the wild type and the mutant alleles
that differ by just a single nucleotide.
2. Materials and Methods
2.1. Synthesis and Purification of RNA Oligonucleotides.
The oligoribonucleotides were synthesized according to
the routine phosphoramidite approach [47], using LCA
CPG glass support and commercially available nucleoside
phosphoramidites (ChemGenes). Synthesis was performed
on the Gene World DNA synthesizer under the conditions
recommended by the manufacturer. Oligonucleotides were
cleaved from the solid support as 5′-DMT-derivatives, then
deprotected and purified according to the described pro-
cedure [48]. Support-bound oligonucleotides were treated
with 33% ethanolic methylamine (Sigma-Aldrich) and
DMSO 1 : 1 (v : v) mixture at 65◦C for 15min and then
with triethylamine-trihydrofluoride (Sigma-Aldrich) at 65◦C
for 15min. The reaction mixture was frozen at −20◦C
for 30min, quenched with cold 1.5M NH4HCO3 and
poured into a conditioned SepPak cartridge (Waters).
Shorter oligomers were eluted with 14% CH3CN in 50mM
CH3COONa and 50mM NaCl. The remaining oligomer
was treated with 2% aqueous TFA (trifluoroacetic acid) for
15min at room temperature and washed with water, 1M
NaCl, and water. The product was eluted from the cartridge
with 30% CH3CN. The structure and purity of oligomers
were confirmed byMALDI-TOFmass spectroscopy (Table 1)
and by 20% polyacrylamide/7M urea gel electrophoresis
(data not shown).
2.2. Assembly of siRNA. siRNA duplexes were assembled
in phosphate saline buffer (PBS, without Ca2+ and Mg2+)
by mixing equimolar amounts of complementary oligonu-
cleotides, heating at 95◦C for 2min, and slow cooling down
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Table 1: Sequences and MALDI-TOF MS data of oligoribonucleotides used for the preparation of siRNAs. The position of mismatch for
pairing with the wild type gene is indicated in bold and underlined.
siRNA Strand Sequence
MW MALDI-TOF MS
(calculated) m/z
P1
S: 5′-GUGGUUGGUAAAGCCUCAGTT-3′ 6724.1 6768.3
As: 3′-TTCACCAACCAUUUCGGAGUC-5′ 6587.2 6592.1
P2
S: 5′-UGUGGUUGGUAAAGCCUCATT-3′ 6685.1 6681.9
As: 3′-TTACACCAACCAUUUCGGAGU-5′ 6611.2 6608.2
P3
S: 5′-UUGUGGUUGGUAAAGCCUCTT-3′ 6662.1 6660.3
As: 3′-TTAACACCAACCAUUUCGGAG-5′ 6634.2 6632.1
P4
S: 5′-GUUGUGGUUGGUAAAGCCUTT-3′ 6702.1 6697.1
As: 3′-TTCAACACCAACCAUUUCGGA-5′ 6594.2 6592.6
P5
S: 5′-UGUUGUGGUUGGUAAAGCCTT-3′ 6702.1 6699.6
As: 3′-TTACAACACCAACCAUUUCGG-5′ 6594.2 6590.5
P6
S: 5′-GUGUUGUGGUUGGUAAAGCTT-3′ 6742.0 6736.5
As: 3′-TTCACAACACCAACCAUUUCG-5′ 6554.3 6552.9
P7
S: 5′-AGUGUU C UGGUUGGUAAAGTT-3′ 6766.0 6764.0
As: 3′-TTUCACAACACCAACCAUUUC-5′ 6515.3 6514.1
P8
S: 5′-CAGUGUUGUGGUUGGUAAATT-3′ 6726.1 6723.5
As: 3′-TTGUCACAACACCAACCAUUU-5′ 6555.3 6552.7
P9
S: 5′-ACAGUGUUGUGGUUGGUAATT-3′ 6726.1 6725.1
As: 3′-TTUGUCACAACACCAACCAUU-5′ 6555.3 6553.2
P10
S: 5′-UACAGUGUUGUGGUUGGUATT-3′ 6703.0 6705.5
As: 3′-TTAUGUCACAACACCAACCAU-5′ 6578.3 6578.6
P11
S: 5′-CUACAGUGUUGUGGUUGGUTT-3′ 6679.0 6720.2
As: 3′-TTGAUGUCACAACACCAACCA-5′ 6617.2 6615.5
P12
S: 5′-UCUACAGUGUUGUGGUUGGTT-3′ 6679.0 6679.4
As: 3′-TTAGAUGUCACAACACCAACC-5′ 6617.2 6617.1
P13
S: 5′-UUCUACAGUGUUGUGGUUGTT-3′ 6640.1 6640.2
As: 3′-TTAAGAUGUCACAACACCAAC-5′ 6641.3 6664.1
P14
S: 5′-UUUCUACAGUGUUGUGGUUTT-3′ 6601.1 6601.1
As: 3′-TTAAAGAUGUCACAACACCAA-5′ 6400.0 6701.1
P15
S: 5′-UUUUCUACAGUGUUGUGGUTT-3′ 6601.1 6620.4
As: 3′-TTAAAAGAUGUCACAACACCA-5′ 6665.3 6686.7
P16
S: 5′-AUUUUCUACAGUGUUGUGGTT-3′ 6624.1 6669.3
As: 3′-TTUAAAAGAUGUCACAACACC-5′ 6642.3 6640.1
P17
S: 5′-CAUUUUCUACAGUGUUGUGTT-3′ 6584.1 6583.3
As: 3′-TTGUAAAAGAUGUCACAACAC-5′ 6682.2 6679.5
P18
S: 5′-UCAUUUUCUACAGUGUUGUTT-3′ 6545.2 6583.8
As: 3′-TTAGUAAAAGAUGUCACAACA-5′ 6706.2 6705.0
P19
S: 5′-UUCAUUUUCUACAGUGUUGTT-3′ 6545.2 6543.6
As: 3′-TTAAGUAAAAGAUGUCACAAC-5′ 6706.2 6704.4
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to room temperature (∼2 hours). Formation of the resulting
duplexes was confirmed by 4% agarose gel electrophoresis
(data not shown).
2.3. Construction of Plasmids Coding EGFP-PSEN1 Fusion
Gene. Human Presenilin 1 (PSEN1, GenBank NM 000021)
coding sequence containing 1404 base pair (bp) was
isolated from a total RNA, extracted from human cells
(SH-SY5Y, human neuroblastoma) by reverse transcrip-
tion (RT) and polymerase chain reaction (PCR) using
One Step RT-PCR Kit (Qiagen). Reactions were per-
formed in the following conditions—RT: 45◦C 30min,
95◦C 15min, and PCR: amplification 40 cycles (95◦C
30 s; 55◦C 30 s; 68◦C 2min) and termination at 72◦C for
10min. Sequences of primers were as follow: (Fow1) 5′-
AAAAAAGAATTCAGATCTATGACAGAGTTACCTGCAC-
3′ and (Rev1) 5′-AAAAAAGGATCCCTAGATATAAAA-
TTGATGGAATGC-3′. Primers were designed to introduce
EcoR I, Bgl II restriction sites to the 5′ end and BamH I
restriction site to the 3′ end of PSEN1 gene, appropriate
for cloning into pUC18 (Invitrogen) and pEGFP-C1 (BD
Biosciences) plasmids. The cloning process was carried out
using E. coli competent cells, strain TOP10 (Invitrogen). Site-
directed mutagenesis for introducing a point mutation in the
PSEN1 gene (C→G at the position 1174) was performed
using QuikChange Site-Directed Mutagenesis Kit (Strata-
gene) in the conditions recommended by the manufacturer.
Sequences of the mutagenic primers were as follow: 5′-
CATTTTCTACAGTGTTGTGGTTGGTAAAGCCTCAGC-
3′ and 5′-GCTGAGGCTTTACCAACCACAACACTGTA-
GAAAATG-3′. Correctness of inserts sequences (wild type,
Wt-PSEN1, and mutated Mut-PSEN1) was confirmed by
the sequencing reaction (IBB, Warsaw). Inserts coding Wt-
PSEN1 orMut-PSEN1 were introduced at the 3′ end of EGFP
(Enhanced Green Fluorescent Protein) gene in the pEGFP-
C1 expression plasmid. Plasmids pEGFP-PSEN1(1400) and
pEGFP-Mut-PSEN1(1400) were used to study PSEN1 gene
expression changes of in eukaryotic cells. Due to the low level
of the EGFP-PSEN1 (EGFP with full length PSEN1) fusion
protein expression in HeLa cells, a new fusion genes coding
EGFP with shorter fragment of Wt-PSEN1 or Mut-PSEN1
were constructed. To create appropriate plasmids (pEGFP-
Wt-PSEN1(400) and pEGFP-Mut-PSEN1(400)) the frag-
ments of Wt-PSEN1 or Mut-PSEN1 coding region (1061–
1404 nt position) were amplified by polymerase chain reac-
tion (PCR) from the pEGFP-Wt-PSEN1(1400) or pEGFP-
Mut-PSEN1(1400) plasmids, using the following primers:
(Fow2) 5′-AAAAAAGTCGACTAGTAACACCTGAGTCAC-
GAGCTGC-3′ and (Rev1) 5′-AAAAAAGGATCCCTA-
GATATAAAATTGATGGAATGC-3′. PCR products were
digested by Sal I and BamH I restriction enzymes and 344 bp
inserts were cloned into pEGFP-C1 plasmid. The accuracy of
sequences of both inserts was confirmed by the sequencing
reaction (IBB, Warsaw).
2.4. Cell Culture and Transfection Conditions. HeLa (human
cervical carcinoma) cells were cultured in RPMI (GIBCO,
BRL, Paisley) supplemented with 10% FBS (GIBCO, BRL,
Paisley) and antibiotics (penicillin 100 units/mL, strepto-
mycin 100mg/mL, Polfa) at 37◦C and 5% CO2. Twenty-
four hours before the experiment, cells were plated in
96-well plate, (plates with black walls and transparent
bottom, Perkin-Elmer) at the density of 15 × 103 cells
per well. Directly before the transfection, the cell medium
containing antibiotics was replaced with the new one, free of
antibiotics. Transfection was performed using Lipofectamine
2000 transfection reagent (Invitrogen) at a ratio 1.5 : 1 (1.5 μL
of Lipofectamine 2000 per 1 μg of nucleic acid) according
to the manufacturer’s protocol. For dual fluorescence assay
(DFA), HeLa cells were cotransfected with DNA plasmids:
reporter plasmid pDsRed-N1 (BD Biosciences) (15 ng/well)
and pEGFP-Wt-PSEN1(400) (100 ng/well) or pEGFP-Mut-
PSEN1(400) (100 ng/well) and siRNAs (1 nM) dissolved in
OPTI-MEM medium (GIBCO, BRL, Paisley). After 5 hours
of incubation, transfection mixture was replaced with fresh
medium with antibiotics. After next 48 hours of incubation
at 37◦C in 5% atmosphere of CO2, the cells were washed
three times with PBS buffer (without Ca2+ and Mg2+) and
lysed with NP-40 buffer (150mMNaCl, 1% IGEPAL, 50mM
Tris-HCl pH 7.0, 1mM PMSF) overnight at 37◦C. Prepared
cell lysates were used for fluorescence determination.
Two cell lines of human fibroblasts (i) expressing wild
type PSEN1 (CELMA) and (ii) L382V PSEN1 mutant
(NOV4), were cultured in Dulbecco’s MEM (Sigma-Aldrich
Co., Saint Louis, MO), supplemented with 10% FBS and
antibiotics (100 units/mL penicillin and 100mg/mL strep-
tomycin) in 24-well plate at 37◦C and 5% CO2. Before
transfection, the culture medium was replaced with fresh
medium, free of antibiotics. Transfection was performed
using Lipofectamine 2000 transfection reagent (Invitrogen)
and appropriate siRNAs at the ratio 2 : 1. To test the effect
of siRNA on Aβ level, the cells were transfected with siRNAs
(150 or 300 nM). After transfection, cells were incubated for
5-6 hours and then medium with transfection mixture was
replaced with the fresh, culturing medium with antibiotics
and 5% FBS. After 72-hour incubation at 37◦C and 5% CO2,
cells were washed three times with PBS buffer (without Ca2+
and Mg2+), the fresh medium with 0.2% FBS was added
and cells were incubated for the next 24 hours. Then the
culturing medium was collected with 1mM AEBSF (4-(2-
Aminoethyl) benzenesulfonyl fluoride hydrochloride, serine
protease inhibitor, Sigma) for determination of Aβ42 level by
ELISA (Enzyme-linked immunosorbent assay).
2.5. Dual Fluorescence Assay. Fluorescence values of EGFP
and RFP (red fluorescent protein) were determined using
a Synergy HT reader (BIO-TEK). Quantification of data
was done with KC4 software. Excitation and emission
wavelengths for each protein were as follows—EGFP: λEx =
485/20nm and λEm = 528/20nm and RFP: λEx = 530/25nm
and λEm = 590/30nm. The activity of siRNA duplexes
was calculated as the ratio of EGFP to RFP fluorescence
values according to the following equation. Activity of siRNA
(%) = 100%− (sample EGFP-X/RFP : control EGFP-X/RFP)
×100% were (EGFP-X means the fluorescence value of
EGFP-X fusion protein, X = Wt-PSEN1 or Mut-PSEN1).
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Every time an average value of fluorescence was mean of
eight repeats calculated after eliminating extreme values.
Each siRNA activity value given on the plots is the average
of mean values from three independent experiments. The
level of fluorescence (EGFP/RFP) in control cells (transfected
with pDsRed-N1 and pEGFP-Wt PSEN1(400) or pEGFP-
Mut-PSEN1(400) plasmids and control nonsilencing siRNA
duplex) was taken as a reference (100%).
2.6. Determination of Aβ42 Level. Chromogenic sandwich
ELISA kit (Signet Laboratory, Denham, MA) was used
according to the manufacturer’s procedure. To analyze the
level of Aβ42 in conditioned medium (after transfection of
siRNAs) collected as described in p.2.4., the 100 μL samples
of medium were placed in a 96-well ELISA plate, precoated
with a capture antibody (specific to the N-terminus of
human Aβ42 peptide) and incubated at 4◦C for 16 hours.
After washing, a reporting antibody, that binds to the C-
terminus of Aβ42, was added. After incubation for the next
2 hours and extensive washing, a horseradish peroxidase
conjugated secondary antibody was added. Color developed
with substrate o-phenylenediamine was measured at λ492
using a Synergy HT reader, and received data were quantified
using KC4 software. The siRNA activity was calculated as
the ratio of Aβ42 in experimental and control sample (cells
treated with transfection reagent only). Results showed at
the graph (Figure 6) are the average of two independent
experiments.
2.7. FACS Flow Cytometry. For flow cytometry assay, HeLa
cells were seeded on the 6-well plate (3 × 105 cells per well)
and cotransfected with appropriate plasmids: pDsRed-N1
(0.5 μg/well) and pEGFP-Wt-PSEN1(400) or pEGFP-Mut-
PSEN1(400) (1.5 μg/well) and siRNAs: control nonsilencing
siRNA and duplexes targeting the mutated form of PSEN1
transcript such as siRNA no 2, 7, 10, 11, 12 and 16
(denoted as P2, P7, P10, P11, P12, and P16, resp.) (5 nM)
using Lipofectamine 2000, according to the manufacturer’s
protocol. After 48 hour incubation at 37◦C and 5% CO2,
cells were washed three times with ice cold PBS buffer
(without Ca2+ and Mg2+) and collected for flow cytometry
assay. Flow cytometry was performed on BD FACS Calibur
Flow Cytometry System (Becton Dickinson) using Ar-ion
laser (488 nm). Fluorescence dot plots and histograms were
generated using Cell Quest software.
2.8. Statistical Analysis. The values of EGFP-PSEN1 fluores-
cence were normalized to the values of RFP fluorescence for
each studied sample. All results are given as a percent of the
fluorescence of sample toward fluorescence of control cells
(transfected with Lipofectamine 2000 only or with control,
nonsilencing siRNA) with standard deviation of mean. The
Shapiro-Wilks’ W test was used to analyze the normality
of distribution of the resulted data. Statistical analysis of
differences between two groups of data (Wt-PSEN1 versus
Mut-PSEN1) were calculated by the use the Student’s t-test
(for data with normal distribution) or by the nonparametric
Mann-Whitney’s U-test. The differences with P < .05 were
considered as statistically significant.
3. Results and Discussion
3.1. Construction of the Expression Plasmids Carrying the Wild
Type and Mutant Alleles of PSEN1 Gene. The wild type and
1174 C→G, L392V mutant of PSEN1 gene were selected as a
model system to assess the allele-specificity of the siRNAs and
to select the duplexes, that discriminate between two target
RNAs differing by the single nucleotide. Plasmids coding the
wild type and mutant type genes were prepared as described
in Section 2. At first, the full length (1404 bp) wild type and
mutant PSEN1 genes were cloned in ORF (open reading
frame) at the 3′-UTR of EGFP gene coded in the pEGFP-C1
plasmid. The expression products were designed to contain
the EGFP protein fused by five amino acids linker (-Ser-Gly-
Leu-Arg-Ser-) with intactWt-PSEN1 orMut-PSEN1 protein.
The resulting plasmids pEGFP-Wt-PSEN1(1400) or pEGFP-
Mut-PSEN1(1400) were cotransfected with the reporter
plasmid pDsRed-N1 coding RFP, into HeLa cells. After 48
hour incubation, only very low levels of the fluorescence
of EGFP fusion proteins were observed. Probably, attaching
the 473-aa long polypeptide chain at the C-termini of EGFP
resulted in abnormal folding of the fusion protein and, in
consequence, in the low level of the fluorescence. Therefore
these plasmids were excluded from further experiments
and new, shorten fusion genes were prepared, containing a
344 bp 3′-terminal fragment of PSEN1 gene, in the wild-
type and mutated versions, attached to the 3′-UTR of EGFP
gene in the pEGFP-C1 expression plasmid. Additionally,
the translation stop codons TAG and TAA were introduced
into EGFP upstream of the coding sequence of fragment of
the PSEN1 gene. The length of the obtained plasmids was
confirmed by 0.5% agarose gel electrophoresis (Figure 1).We
expected the high value of the fluorescence of EGFP in the
case of intact fusion transcript EGFP-PSEN1 and low or no
fluorescence if the fusion transcript is degraded by RNAi.
Results of the dual fluorescence assay for all reporter plas-
mids (pEGFP-Wt-PSEN1(1400); pEGFP-Mut-PSEN1(1400);
pEGFP-Wt-PSEN1(400) and pEGFP-Mut-PSEN1(400)) are
shown in Figure 2. Plasmids pEGFP-Wt-PSEN1(400) and
pEGFPMut-PSEN1(400) were used in further studies of the
siRNA activity toward the Wt- and Mut-PSEN1 genes both
expressed in HeLa cells.
3.2. Design, Synthesis, and Evaluation of the Activity of siRNAs
Targeting Mutant Allele of PSEN1
3.2.1. siRNA Molecules. We synthesized a set of 19 siRNAs,
designed across the L392V point mutation in the human
PSEN1 gene. The L392V mutant contains a guanosine at
the position 1174 of mRNA, whereas the wild-type mRNA
bears a cytidine at that position. Each siRNA antisense strand
was fully complementary to the mutant PSEN1 mRNA,
but in relation to the wild type mRNA contained a C:C
mismatch (Figure 3). The structure of all tested oligonu-
cleotides was confirmed by mass spectrometry (MALDI-
TOF MS, Table 1), and their purity was assessed on 20%
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5075 bp
4731 bp
Figure 1: Electrophoretic analysis of the plasmids carrying the
wild type (Wt) and mutant (Mut) alleles of the PSEN-1 gene and
original, commercially available plasmids: (1) pEGFP-C1 (4731 bp),
(2) pDsRed-N1 (4689 bp) (3) pEGFP-Wt-PSEN1(400) (5075 bp),
(4) pEGFP-Mut-PSEN1(400) (5075 bp) (0.5% agarose gel).
pEGFP-Mut-PSEN1(1400)
0 20 40 60 80 100 120 140
EGFP/RFP (%)
Exspression of EGFP-PSEN1
fusion genes in HeLa cells
pEGFP-Wt-PSEN1(400)
pEGFP-Mut-PSEN1(400)
pEGFP-Wt-PSEN1(1400)
Figure 2: Comparison of the fluorescence values of EGFP-PSEN1
fusion proteins expressed from the EGFP-PSEN1 gene coding
plasmids. Plasmids pEGFP-Wt PSEN1(1400) and pEGFP-Mut
PSEN1(1400) contain full length (1404 bp) wild type (Wt) and
mutein (Mut) (C→G 1174) PSEN1 gene introduced at the 3′-UTR
of EGFP gene; plasmids pEGFP-Wt-PSEN1(400) and pEGFP-Mut-
PSEN1(400) contain insert with shorter version (344 bp) of PSEN1
(Wt or Mut) introduced at the 3′-UTR of the EGFP gene.
denaturing PAGE (data not shown). All siRNA duplexes
used in these experiments had the typical structure of 19 bp
fully complementary duplex with 2-nt overhangs at each
3′-end with typically used two thymidine units (TT). This
approach was intended for the proper interaction of RNA
duplex with proteins of RNAi machinery [49]. Ago2 protein,
the main catalytic core of the RISC (RNA-induced silencing
complex) binds the guide strand, which leads the complex
to the complementary mRNA strand. Ago2-mediated RNA
cleavage requires perfect Watson-Crick base pairing between
the guide strand of siRNA and the target mRNA, spanning
both, the seed region (positions from 2nd to 8th nucleotide)
and the cleavage site (phosphate group opposite to the
internucleotide linkage located between 10th and 11th
nucleotide, counted from the 5′-end of the guide strand [50].
3.2.2. Silencing Activity Measured in the Dual Fluorescence
Assay. In order to evaluate the silencing activity of siRNAs,
we used the already described dual fluorescence reporter
system [51–55]. This assay is based on the measurement of
the relative fluorescence intensity of EGFP and RFP proteins,
expressed from exogenously delivered plasmids cotransfected
together with siRNA. In our case, the HeLa cells were
transfected with pEGFP-Wt-PSEN1(400) or pEGFP-Mut-
PSEN1(400) and pDsRed-N1 as well as with P1–P19 siRNAs
listed in Table 1 and Figure 3. The results of the fluorescence
measurements are shown in Figure 4. The P8–P11 siRNAs,
with the perfect complementarity to the mutant allele, but
in the same time with one mismatch (cytidine:cytidine, C:C)
to the wild type gene placed at the central positions of the
duplex, efficiently silenced the mutant gene (up to 90%,
P < .0001), while only slightly reducing the wild type gene
expression (silencing ca. 10–30%, P < .0001). Interestingly,
duplexes P1 and P2 showed a very strong silencing property
towards both—the wild type and the mutated genes. This
high silencing activity of the latter duplexes may be related
to the high thermodynamic asymmetry of the duplex ends
(discussed in Section 3.4) in comparison to other siRNA
duplexes or to the better access of siRNA to the target region
of the mRNA. The remaining P3, P5, P6, P7, and P12–P19
duplexes were almost inactive in relation to both the wild
type as well as the mutant gene.
3.2.3. Silencing Activity Measured by Flow Cytometry. HeLa
cells cotransfected with pEGFP-Wt-PSEN1(400) or pEGFP-
Mut-PSEN1(400), pDsRed-N1 plasmids, and with selected
duplexes P2, P7, P8, P9, P10, P11, P12, and P16 siRNAs
were analyzed by FACS flow cytometry. The amount of cells
containing the EGFP and RFP fluorescence in the tested
samples (cells transfected with siRNAs) was determined
and compared with the amount of cells in control samples
(cells treated with transfection reagent only or treated
with nonsilencing, control siRNA). The duplexes perfectly
complementary to the L392V PSEN1 mRNA but with one
mismatch (C:C) towards the wild type gene, lockated at
the central position of the antisense strand (as P8 and P9),
exhibited the highest allele-specificity and silencing efficiency
exclusively towards the mutant gene (Figure 5). Thus, the
data obtained in this analysis confirmed the above described
results.
3.2.4. Evaluation of the Level of Aβ42 by ELISA. The activity
of siRNAs towards endogenous target genes was evaluated by
the measurement of the level of extracellular Aβ42 released
from the transfected cells. For this purpose human fibrob-
lasts derived from the patients with FAD, carrying L392V
mutantion in PSEN1 (NOV4), were used [56, 57]. Human
fibroblasts, carrying the wild type of PSEN1 (CELMA),
derived from healthy individuals were used as a control
[56, 57]. The amount of the Aβ42 peptide was determined
by the sandwich ELISA test. The normalized results obtained
for this assay for both types of cells transfected with control,
nonsilencing, and P10 siRNA are shown in Figure 6. The
amount of the Aβ42 peptide released from NOV4 cells
(NOV4Aβ42) transfected with P10 siRNA was reduced by
ca. 40% (P = .000021) compared to fibroblasts NOV4
treated only with Lipofectamine 2000 or transfected with
control nonsilencing siRNA. Application of siRNAs directed
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Figure 3: The sequences of the antisense strands of siRNAs used in studies. The guide strand of each siRNA is fully complementary to the
mutant (C→G) PSEN1 transcript and it has one mismatch (C:C) in respect to the wild type gene. The region between 2nd to 8th nucleotide,
counted from the 5′-end of the antisense strand of siRNA is known as the seed region.
towards the mutated PSEN1 gene did not influence the
level of Aβ42 released from control fibroblasts (CELMAAβ42),
which was much lower than in NOV4 cells (both NOV4Aβ42
and CELMAAβ42 levels are showed at the graph as 100%).
The results obtained may constitute a proof-of-concept that
silencing of the mutant allele of PSEN1, exerted by fully
complementary siRNA, led to the reduced expression of the
mutant Presenilin1, which in consequence gave less of the
toxic Aβ42 product.
3.3. Modulation of Allele-Specific Activity of siRNAs by
Chemical Modifications
3.3.1. Modification of siRNA with 2-Thiouridine. The allele-
specific activity was evaluated for siRNA modified with
naturally occurring 2-thiouridine (s2U) nucleoside. As it
has been already demonstrated, s2U, due to preferred C3′-
endo conformation of the ribose ring, improves the thermo-
dynamic stability of s2U-containing double stranded RNA
helices [52, 58, 59]. Additionally, s2U unit, when present in
the anticodon region of transfer RNA (tRNA), enhances its
specificity of Watson-Crick base pairing with A and restricts
wobble base pairing with G [58, 59]. We choose P10 duplex,
which previously has shown satisfactory discrimination
between wild type and mutant alleles, and introduced the
s2U unit at the position 18 of the antisense strand (P10-
thio) (Figure 7(b)). The s2U modification at this position
of the RNA duplex (the 3′-end of duplex) improves its
thermodynamic asymmetry and facilitates incorporation of
the antisense strand into the RISC complex [52]. Moreover,
s2U introduction can impact positively on the uptake of
siRNA into cells, due to the presence of sulfur moiety, which
increases the hydrophobic properties of themolecule. Results
of the dual fluorescence assay performed for HeLa cells
transfected with P10-thio siRNA are presented in Figure 7(c).
It is clearly shown that introduction of the s2U unit at
the 3′-end of the antisense strand of P10 siRNA further
improved allele discrimination (∼10%) due to the increased
thermodynamic asymmetry of the duplex.
3.3.2. Silencing Activity of Sulfur-Containing siRNA Evaluated
by Fluorescence Microscopy. The activity of the selected
siRNAs was also observed by the fluorescence microscopy.
Figure 8 shows fluorescence images of the fixed samples
obtained from HeLa cells transfected with P10, P10-thio,
and P11 siRNA duplexes. Here again, the cells carrying
the wild type gene (EGFP-Wt-PSEN1(400)) expressed green
fluorescent protein at the high level and independently of the
siRNA sequence. In contrast, slides containing cells express-
ing the mutant gene (EGFP-Mut-PSEN1(400)) have shown
less fluorescently labeled cells, and the most pronounced
result was obtained for cells transfected with the P10-
thio siRNA duplex, confirming high discrimination ratio of
siRNA against the wild type and mutant alleles of the PSEN1
gene.
3.3.3. Modification of siRNA with Wobble Base Pair. The
region near the central positions at the antisense strand
of siRNA (10th-11th) is interesting, primarily from the
perspective of a nucleolytic reaction catalyzed by Ago2 [49,
50]. To investigate the influence of correct base pairing in this
region on allele-specificity and the overall activity of RNA
duplex, the wobble type modification was introduced at the
two positions of the antisense strand, namely position 9 or
11 counting from the 5′end, adjacent to the mutation site
(Figure 9(a)). According to our earlier assumption, introduc-
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s’yentihW-nnaM7P U-test .000173 P17 Mann-Whitney’s U-test .220432
s’yentihW-nnaM8P U-test .000025 P18 Student’s t-test .000603
s’yentihW-nnaM9P U-test .000089 P19 Student’s t-test .000019
s’yentihW-nnaM01P U-test .000002
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Figure 4: (a) Comparison of the fluorescence level obtained from analysis of HeLa cells cotransfected with pEGFP-Wt-PSEN1(400) or
pEGFP-Mut-PSEN1(400), pDsRRed-N1 and indicated siRNAs (0—control nonsilencing siRNA and siRNAs targeting the mutated form of
PSEN1 transcript (denoted as P1–P19) (1 nM). Dotted lines at the right panel represent the antisense strands of the used siRNAs. Positions
of the C:C mismatch between the guide strand of siRNA and the wild-type PSEN1 mRNA are indicated by the black dots. The level of the
relative EGFP/RFP fluorescence of the cells transfected with control non-silencig siRNA was used as 100%. The results are mean values from
three independent experiments. (b) Statistical analysis of differences between two groups of data (Wt-PSEN1 versus Mut-PSEN1) calculated
by the use the Student’s t-test (for data with normal distribution) or by the nonparametric Mann-Whitney’s U-test. The differences with
P < .05 were considered as statistically significant.
tion of such structural disorder into RNA duplex reduces
the thermodynamic stability of the duplex and weakens the
interaction between guide strand and the target mRNA.
We supposed that the wobble modification could increase
the allele-specificity of siRNAs targeted towards the mutant
gene. Instead, we observed significant deterioration of the
silencing activity of both modified siRNAs (P10W9 and
P10W11) (Figure 9(b)). Most probably, introduced disorder
in the base pairing like wobble G:U considerably disturbs the
recognition of the double stranded RNA helix (containing
mRNA and the antisense strand of siRNA) by Ago2, what
results in inhibition of the silencing process.
3.4. Thermodynamic Properties of siRNA Duplexes (P1–P19)
versus Their Silencing Activity. Thermodynamic stability of
RNA duplexes and secondary structure of RNA are often pre-
dicted by using free-energy parameters from a near-neighbor
model [60]. To assess the relative thermodynamic stability
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Table 2: Differences between the free Gibbs energy of 5′-end and 3′-end of the duplex (resp. to the polarity of the antisense
strand), calculated independently for three and for four consecutive base pairs shown for each duplex (ΔΔG37◦C = ΔG37◦C (5′-end) −
ΔG37◦C (3′-end)). The values of ΔG37◦C were calculated according to [60].
siRNA Sequence
ΔΔG37◦C (kcal/mol) ΔΔG37◦C (kcal/mol)
(for 3 bp) (for 4 bp)
P1
5′-GUGG—UCAGTT-3′
1 1.6
3′-TTCACC—AGUC-5′
P2
5′-UGUG—CUCATT-3′ −0.2 −0.1
3′-TTACAC—GAGU-5′
P3
5′-UUGU—CCUCTT-3′ −1.9 −2.7
3′-TTAACA—GGAG-5′
P4
5′-GUUG—GCCUTT-3′ −0.5 −1.8
3′-TTCAAC—CGGA-5′
P5
5′-UGUU—AGCCTT-3′ −3 −3.8
3′-TTACAA—UCGG-5′
P6
5′-GUGU—AAGCTT-3′ −1.2 0
3′-TTCACA—UUCG-5′
P7
5′-AGUG—AAAGTT-3′
0.7 1.6
3′-TTUCAC—UUUC-5′
P8
5′-CAGU—UAAATT-3′
1.7 2.7
3′-TTGUCA—AUUU-5′
P9
5′-ACAG—GUAATT-3′
1.4 1
3′-TTUGUC—CAUU-5′
P10
5′-UACA—GGUATT-3′
0 −1.1
3′-TTAUGU—CCAU-5′
P11
5′-CUAC—UGGUTT-3′ −1.7 −1.4
3′-TTGAUG—ACCA-5′
P12
5′-UCUA—UUGGTT-3′ −0.7 −0.5
3′-TTAGAU—AACC-5′
P13
5′-UUCU—GUUGTT-3′
0.5 0.1
3′-TTAAGA—CAAC-5′
P14
5′-UUUC—GGUUTT-3′ −0.7 −1.3
3′-TTAAAG—CCAA-5′
P15
5′-UUUU—UGGUTT-3′ −2.7 −3.6
3′-TTAAAA—ACCA-5′
P16
5′-AUUU—GUGGTT-3′ −3.4 −4.6
3′-TTUAAA—CACC-5′
P17
5′-CAUU—UGUGTT-3′ −1.2 −2.1
3′-TTGUAA—ACAC-5′
P18
5′-UCAU—UUGUTT-3′
0.7 0.7
3′-TTAGUA—AACA-5′
P19
5′-UUCA—GUUGTT-3′
0.5 0.2
3′-TTAAGU—CAAC-5′
of the duplex ends, we counted up the theoretical values of
Gibbs free energy, ΔG37◦C, of three and of four base pairs at
the 5′-end and the 3′-end of siRNA (numbering according
to the guide strand polarity) for each duplex used in our
studies, by the use of the method recommended by Freier
et al. [60]. The standard-state free energy of helix formation
was counted as the sum of the following terms: (i) a free-
energy change for helix initiation associated with forming the
first base pair in the duplex, (ii) the sum of propagation free
energies for forming each subsequent base pair, and (iii) free-
energy increments for unpaired terminal nucleotides. Then,
differences between the free Gibbs energy of the 5′-end and
the 3′-end for each duplex were calculated independently
for three and four consecutive base pairs according to the
following equation: ΔΔG37◦C = ΔG37◦C (5′-end) − ΔG37◦C
(3′-end). The results of this analysis are shown in Table 2
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Figure 5: Results of flow cytometry assay. HeLa cells were cotrans-
fected by pEGFP-Wt-PSEN1(400) or pEGFP-Mut-PSEN1(400),
pDsRed-N1, and indicated siRNAs, using Lipofectamine 2000 as
a transfection reagent (details described in Section 2). HeLa cells
containing both, the EGFP and RFP fluorescence, were counted in
the BD FACS Calibur Flow Cytometry System (Becton Dickinson)
using Ar-ion laser (488 nm). Fluorescence dot plots were generated
using Cell Quest software.
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Figure 6: The normalized values of the extracellular Aβ42 levels
in medium of cells transfected with the siRNA duplexes. Human
fibroblasts expressing endogenously the wild type PSEN1 gene
(CELMA) and L392V mutant (NOV4) were cultured in the
presence of P10, P10-thio, and control nonsilencing siRNA duplexes
(150 and 300 nM). After 48-hour incubation, the culturing medium
was collected with 1mM AEBSF, and the level of Aβ42 was
measured by sandwich ELISA test. Data are presented as percentage
values to control cells treated with lipofectamine only. The results
are mean values from two independent experiments. Statistical
analysis of differences between two groups of data (Wt-PSEN1
versus Mut-PSEN1) were calculated by the use of Student’s t-test
(data with normal distribution). All differences were considered as
statistically significant.
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Figure 7: (a) 2-Thiouridine (s2U) structure, R = β-D-ribo-
furanoside residue. (b) Sequences of the P10 and P10-thio modified
siRNAs. (c) Comparison of the relative (EGFP/RFP) fluorescence
in HeLa cells transfected with reporter plasmids: pEGFP-Wt-
PSEN1(400) or pEGFP-Mut-PSEN1(400), pDsRed-N1 and siRNA:
P10 and P10-thio (1 nM). Dotted lines represent the antisense
strands of the used siRNAs. Positions of the C-C mismatch
between the guide strand of siRNA and the wild-type PSEN1
mRNA are indicated by the black dots. Red dot represents the
site of the s2U modification at the antisense strand. The level
of the relative EGFP/RFP fluorescence in cells transfected with
control nonsilencing siRNA was used as 100%. Statistical analysis
of differences between two groups of data (Wt-PSEN1 versus Mut-
PSEN1) were calculated by the use the Student’s t-test (for data with
normal distribution) or by the nonparametric Mann-Whitney’s U-
test. The differences with P < .05 were considered as statistically
significant.
and in Figure 10. The positive ΔΔG37◦C values indicate the
higher thermodynamic stability of the 3′-end of the duplex,
thus the antisense strand should be selected as the guide
strand and the siRNA duplex should be more active. The
negative values of ΔΔG37◦C mean the higher thermodynamic
stability of the 5′-end of the duplex, thus the antisense strand
is not preferred to be selected as a guide strand and, in
consequence, the siRNA duplex would be expected to be less
active towards the target gene. Comparison of the two graphs
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Figure 8: Silencing effects of siRNAs directed towards the Mut-PSEN1 (C→G1174). Fluorescence microscopy image of cells expressing the
wild type and mutant fusion protein in the presence of siRNA: P10, P10-thio, and P11.
representing the silencing activity (Figure 10(a)) and the
thermodynamic features of the duplex ends (Figure 10(b))
can explain observed differences in the activity of the used
siRNAs, for example, duplexes P3–P6 and P14–P17 are
characterized by the negative values of Gibbs free energy and
are neglectably active. On the contrary, duplexes P1, P2, and
P7–P10 showing positive or close to zero values of Gibbs
free energy are more active as RNAi triggers. In some cases,
silencing efficacy of siRNA duplexes depends on other factors
as the secondary structure of target mRNA or availability of
target sequence for RNAi proteins [61]. Also the other, not
identified factors may govern the silencing process of given
mRNA targets with short interfering RNAs.
4. Conclusions
Dominantly inherited disorders, caused by the presence
of the toxic mutant allele besides the wild type gene,
constitute attractive targets for allele-specific gene silencing.
Gene therapy aimed at the elimination of the mutant allele
causing the disease can be achieved by an RNA interference
technology. Clinical success of such therapies dependsmostly
on the ability of RNAi to discriminate between the wild
type and mutant alleles. In this paper, we demonstrate the
allele-specific silencing activity of the short interfering RNAs
directed towards mutant allele of PSEN1 gene. L392V PSEN1
mutant gene contains 1174 C→Gmutation, which results in
12 International Journal of Alzheimer’s Disease
- UACAGUGUUGUGGUUGGUATT-
-TTAUGUCACAACACCAACCAU-
- UACAGUGUUGUGGUUGGUATT-
-TTAUGUCACAACGCCAACCAU-
-UACAGUGUUGUGGUUGGUATT-
-TTAUGUCACAGCACCAACCAU-
P10W11
P10W9
P10
3′
3′
3′
5′
5′
5′
5′
5′
5′
3′
3′
3′
(a)
0 20 40 60 80 100 120 140
Control
siRNA
P10W11
P10W9
P10
EGFP/RFP (%)
pEGFP-Wt-PSEN1
pEGFP-Mut-PSEN1
siRNA (Wt-PS1 versus MutPS1) Test name P value
s’yentihW-nnaM9W01P U-test .084761
s’yentihW-nnaM11W01P U-test .004816
s’yentihW-nnaM01P U-test .000000
(b)
Figure 9: (a) Sequences of the P10W9 and P10W11 siRNAs
modified in the central domain at the position 9 or 11; A is replaced
by G (in red) to generate the wobble base pair with complementary
mRNA strand. (b) Comparison of the florescence levels obtained
after co-transfection of HeLa cells with pEGFP-Wt-PSEN1(400) or
pEGFP-Mut-PSEN1(400), pDsRed-N1 and indicated siRNAs (P10,
P10W9, or P10W11). Dotted lines represent the antisense strands of
the used siRNAs. Positions of the C-C mismatch between the guide
strand of siRNA and the wild-type PSEN1 mRNA are indicated by
the black dots. Red dots represent the sites of the wobble base pairs
between the guide strand of siRNA and the wild- ormutated-type of
PSEN1 mRNA. The level of the relative EGFP/RFP fluorescence in
cells transfected with control nonsilencing siRNAwas used as 100%.
The results are mean values from three independent experiments.
Statistical analysis of differences between two groups of data (Wt-
PSEN1 versus Mut-PSEN1) were calculated by the use by the
nonparametric Mann-Whitney’s U-test. The differences with P <
.05 were considered as statistically significant.
amino acid substitution, Leu to Val, at the position 392 of
polypeptide chain of the protein. This mutation was found
in patients with early onset FAD. At first, we synthesized
a set of siRNAs, designed across the point mutation and
determined their activity towards the mutant and wild type
genes by a dual fluorescence assay, flow cytometry assay,
and fluorescence microscopy images. The most active and
allele-specific were the siRNA duplexes fully complementary
to the target gene, which paired with the wild type allele
with the C:C mismatch located in the central part of the
mRNA-siRNA duplex (P8–P11). These duplexes silenced the
mutant gene up to 90% and only slightly reduced the wild
type gene, up to 10–30%. Introduction of the 2-thiouridine
nucleoside into the 3′-end of the siRNA duplex (in respect
to the polarity of the antisense strand) increased silencing
activity of the duplex and discrimination ratio between the
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Figure 10: Comparison of the activity of siRNAs targeted Mut-
PSEN1 gene (a) with their thermodynamic data (b). siRNAs were
fully complementary to the Mut-PSEN1 transcript. Differences
between the free Gibbs energy of 5′-end and 3′-end of the duplex
(resp. to the polarity of the antisense strand) were calculated
for three and for four consecutive base pairs: (ΔΔG37◦C =
ΔG37◦C (5′-end)− ΔG37◦C (3′-end)) (compare with Table 2).
wild type and mutant allele (P10-thio). The wobble base
pair modification introduced at the 9 or 11 positions of
the antisense strand (P10W9 and P10W11), adjacent to the
mutation site, reduced the thermodynamic stability of the
duplex.We observed significant deterioration of the silencing
activity of both modified siRNAs. Most probably, introduced
disorder in the base pairing (G:U) considerably disturbed the
recognition of the double stranded RNA helix (containing
mRNA and the antisense strand of siRNA) by Ago2, what
resulted in inhibition of the silencing process. The activity
of the screened siRNAs was also evaluated by measurement
of the level of extracellular Aβ42 released from the primary
fibroblasts, carrying the (L392V) PSEN1 mutant (NOV4) in
comparison to control fibroblasts (CELMA), carrying the
wild type PSEN1, determined by ELISA. The normalized
results obtained for NOV4 cells transfected with P10 and
P10-thio siRNA showed reduced amount of Aβ42 by ca.
40% compared to the control fibroblasts treated only with
transfection reagent. This result is a proof-of-concept that
silencing of the mutant allele of PSEN1, exerted by fully
complementary siRNA, led to reduced expression of the
mutant Presenilin 1, which in consequence gave less of the
toxic Aβ42 product.
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